Alladin by sumser
6-Allyl-6-nor-lysergic acid diethylamide (also known as N-allyl-nor-lysergic acid N,N-diethylamide,[1] N-allyl-nor-LSD,[1] or commonly as AL-LAD[1]) is a novel psychedelic substance of the lysergamide class. AL-LAD is chemically similar to LSD and has a similar mechanism of action, working primarily by binding to serotonin receptors in the brain.
AL-LAD was first investigated in 1984 by Andrew J. Hoffman and David Nichols as part of a series of LSD analogs, which also included ETH-LAD and PRO-LAD.[2] Its activity in humans was later documented by Alexander Shulgin in his book TiHKAL ("Tryptamines I Have Known and Loved"), in which it is described as "considerably less dramatic".[3] In 2013, AL-LAD appeared for sale on the research chemical market,[4] where it has been commonly marketed alongside lysergamides such as 1P-LSD, ALD-52 and ETH-LAD as a legal, grey-market alternative to LSD.
User reports describe the effects of AL-LAD as similar to those of LSD with some subtle differences. It is thought to either be equally or moderately less potent than LSD itself, with an active dose reported at between 75 and 150 micrograms. It is often described as being more visually-oriented but with a less introspective headspace. It also has a moderately shorter duration and is generally considered to be a less anxiety-provoking and challenging version of LSD.
Very little data exists about the pharmacological properties, metabolism, and toxicity of AL-LAD. While it is often characterized by users as being generally more recreational and non-threatening compared to LSD, it is highly advised to approach this highly potent hallucinogenic substance with the proper amount of precaution and harm reduction practices if using it.
psychonautwiki.org/wiki/AL-LAD
